N/A
Completed N=17
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Kidney Cancer · Carcinoma, Renal Cell
Source: ClinicalTrials.gov NCT00537056 ↗
Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcomePrimary: F-18 FDG Tumor Uptake (SUV Max) — 9.8; -18.9; 34.0 SUVmax
Summary
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY F-18 FDG Tumor Uptake (SUV Max) |
9.8; -18.9; 34.0 | — |
| SECONDARY Histopathology |
17 | — |
| SECONDARY Initial Comprehensive Metabolic Panel |
17 | — |
| SECONDARY Adverse Events |
— | — |
| SECONDARY Tumor Necrosis |
NA | — |
| SECONDARY Tumor Size by Computed Tomography (CT) Scan |
NA | — |
| SECONDARY Tumor Size by DCE Magnetic Resonance Imaging (MRI) Scan |
NA | — |
| SECONDARY DCE MRI AUC Peak Flow |
NA | — |
| SECONDARY Initial Tumor Size |
NA | — |
Eligibility Criteria
Inclusion Criteria:- Measurable disease by RECIST criteria
- Pathologic diagnosis of renal cell cancer
- Advanced (stage IV) renal cell cancer
- Karnofsky performance status of (KPS>70)
- Consent to participate in the clinical trial Exclusion Criteria:- Patients who cannot complete a PET/CT scan.
- Pregnant women.
- Healthy volunteers.
- Patients participating in other research protocols will be excluded from this study.
- Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications for MRI.
Data sourced from ClinicalTrials.gov (NCT00537056). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.